Compare Stocks: ALZN, ATOS, KYNB, and NXTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.34	$1.61	$0.84 ▼ $2.68	$6.47M	0.27	114,508 shs	13,299 shs
ATOS Atossa Genetics	$2.44 +0.8%	$2.40	$1.70 ▼ $18.00	$24.35M	1.27	66,357 shs	265,555 shs
KYNB Kyntra Bio	$6.11 +2.5%	$7.30	$5.62 ▼ $11.65	$24.74M	1.05	26,366 shs	6,565 shs
NXTC NextCure	$7.18 +5.9%	$6.32	$1.55 ▼ $15.74	$25.93M	1.33	104,058 shs	85,724 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	-2.19%	-21.18%	+13.56%	-47.04%
ATOS Atossa Genetics	0.00%	+4.27%	+4.27%	+2.95%	-85.35%
KYNB Kyntra Bio	0.00%	-3.17%	-23.34%	-19.71%	+610,999,900.00%
NXTC NextCure	0.00%	+41.06%	-1.78%	+264.47%	+4.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.34	$1.61	$0.84 ▼ $2.68	$6.47M	0.27	114,508 shs	13,299 shs
ATOS Atossa Genetics	$2.44 +0.8%	$2.40	$1.70 ▼ $18.00	$24.35M	1.27	66,357 shs	265,555 shs
KYNB Kyntra Bio	$6.11 +2.5%	$7.30	$5.62 ▼ $11.65	$24.74M	1.05	26,366 shs	6,565 shs
NXTC NextCure	$7.18 +5.9%	$6.32	$1.55 ▼ $15.74	$25.93M	1.33	104,058 shs	85,724 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	-2.19%	-21.18%	+13.56%	-47.04%
ATOS Atossa Genetics	0.00%	+4.27%	+4.27%	+2.95%	-85.35%
KYNB Kyntra Bio	0.00%	-3.17%	-23.34%	-19.71%	+610,999,900.00%
NXTC NextCure	0.00%	+41.06%	-1.78%	+264.47%	+4.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,989.55% Upside
ATOS Atossa Genetics	2.20	Hold	$20.33	733.33% Upside
KYNB Kyntra Bio	2.50	Moderate Buy	$37.25	509.66% Upside
NXTC NextCure	2.25	Hold	$19.00	164.62% Upside

Current Analyst Ratings Breakdown

Latest ALZN, ATOS, KYNB, and NXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
10/8/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$41.00
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$41.00
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/31/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/26/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/14/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$0.19 per share	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
KYNB Kyntra Bio	$6.44M	3.84	N/A	N/A	($4.20) per share	-1.45
NXTC NextCure	N/A	N/A	N/A	N/A	$9.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$8.77M	-$2.30	N/A	N/A	N/A	N/A	-277.88%	-184.20%	12/8/2026 (Estimated)
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
KYNB Kyntra Bio	$183.45M	$45.30	0.13	N/A	N/A	2,199.13%	N/A	-47.27%	N/A
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)

Latest ALZN, ATOS, KYNB, and NXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	NXTC NextCure	-$0.90	N/A	N/A	N/A	N/A	N/A
9/10/2026	Q1 2027	ALZN Alzamend Neuro	-$0.56	-$0.68	-$0.12	-$0.68	N/A	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	3.01	3.01
ATOS Atossa Genetics	N/A	5.69	5.69
KYNB Kyntra Bio	N/A	2.69	2.59
NXTC NextCure	N/A	3.47	3.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
ATOS Atossa Genetics	12.74%
KYNB Kyntra Bio	72.71%
NXTC NextCure	42.65%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	1.39%
ATOS Atossa Genetics	9.80%
KYNB Kyntra Bio	4.15%
NXTC NextCure	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	6	4.83 million	4.76 million	No Data
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
NXTC NextCure	40	3.61 million	3.18 million	No Data

ALZN, ATOS, KYNB, and NXTC Headlines

Recent News About These Companies

NextCure stock faces a November court test over its reverse split

October 6, 2026 | ad-hoc-news.deA

NextCure Faces Court Review of Reverse Stock Split

September 28, 2026 | theglobeandmail.com

NextCure Ends Beltsville Lease to Cut Operating Costs

September 3, 2026 | tipranks.com

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

August 10, 2026 | prnewswire.com

NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Purchases 36,303 Shares of Stock

August 4, 2026 | insidertrades.com

Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Acquires $17,050.00 in Stock

July 30, 2026 | insidertrades.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB

July 23, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for ...

July 21, 2026 | caledonianrecord.comC

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB

July 21, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

July 21, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

July 14, 2026 | prnewswire.com

New biotech Avere plots listing via NextCure merger

July 14, 2026 | pharmaphorum.comP

NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders

July 14, 2026 | aol.comA

NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement

July 14, 2026 | blockonomi.com

NextCure announces reverse merger with privately held Avere

July 14, 2026 | seekingalpha.com

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

July 14, 2026 | prnewswire.com

NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan

July 14, 2026 | quiverquant.comQ

NextCure and Avere Therapeutics Announce Definitive Merger and $320 Million Financing to Advance Oral IL-23 Therapy AVR-001

July 14, 2026 | quiverquant.comQ

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALZN, ATOS, KYNB, and NXTC Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$1.34 0.00 (0.00%)

Closing price 10/9/2026 03:56 PM Eastern

Extended Trading

$1.34 -0.01 (-0.37%)

As of 10/9/2026 04:10 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Atossa Genetics NASDAQ:ATOS

$2.44 +0.02 (+0.83%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.50 +0.06 (+2.50%)

As of 10/9/2026 07:59 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Kyntra Bio NASDAQ:KYNB

$6.11 +0.15 (+2.52%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.20 +0.09 (+1.39%)

As of 10/9/2026 07:30 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NextCure NASDAQ:NXTC

$7.18 +0.40 (+5.90%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.08 -0.10 (-1.41%)

As of 10/9/2026 07:55 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, ATOS, KYNB, and NXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, ATOS, KYNB, and NXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, ATOS, KYNB, and NXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALZN, ATOS, KYNB, and NXTC Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Atossa Genetics NASDAQ:ATOS

Kyntra Bio NASDAQ:KYNB

NextCure NASDAQ:NXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, ATOS, KYNB, and NXTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, ATOS, KYNB, and NXTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, ATOS, KYNB, and NXTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALZN, ATOS, KYNB, and NXTC Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Atossa Genetics NASDAQ:ATOS

Kyntra Bio NASDAQ:KYNB

NextCure NASDAQ:NXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools